| Product Code: ETC13299586 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Chemotherapy-Induced Nauvomiting Market was valued at USD 2.3 Billion in 2024 and is expected to reach USD 3.4 Billion by 2031, growing at a compound annual growth rate of 5.10% during the forecast period (2025-2031).
The Global Chemotherapy-Induced Nausea and Vomiting (CINV) market is experiencing steady growth due to the increasing prevalence of cancer worldwide and the subsequent rise in chemotherapy treatments. Key players in the market are focusing on developing innovative antiemetic drugs to effectively manage CINV and improve patient outcomes. The market is also witnessing a trend towards personalized medicine, with a growing emphasis on targeted therapy for CINV based on individual patient characteristics. Factors such as the introduction of new chemotherapy regimens and supportive care guidelines are driving market growth. Additionally, collaborations between pharmaceutical companies and research institutions are playing a crucial role in advancing treatment options for CINV. Emerging markets in Asia-Pacific and Latin America are expected to offer lucrative opportunities for market expansion in the coming years.
The Global Chemotherapy-Induced Nausea and Vomiting (CINV) market is experiencing a shift towards more effective and personalized treatment options. The increasing prevalence of cancer cases worldwide is driving the demand for CINV therapies, leading to the development of innovative drugs and formulations. Key trends include the adoption of antiemetic drugs with improved efficacy and reduced side effects, as well as the introduction of novel therapies such as neurokinin-1 receptor antagonists. Additionally, there is a growing focus on combination therapies and supportive care to better manage CINV in cancer patients. Opportunities in the market lie in expanding into emerging markets, developing patient-centric solutions, and leveraging advancements in precision medicine to tailor treatment regimens based on individual patient characteristics, ultimately improving outcomes and quality of life for cancer patients undergoing chemotherapy.
The Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market faces several challenges, including the variability in patient response to antiemetic medications, leading to the need for personalized treatment approaches. Additionally, the high cost of CINV medications and potential side effects contribute to treatment non-adherence among patients. Another challenge is the limited effectiveness of current antiemetic drugs for certain types of chemotherapy regimens, creating a demand for more innovative and targeted therapies. Moreover, the lack of awareness and education among healthcare providers and patients about CINV management further hinders optimal treatment outcomes. Addressing these challenges requires ongoing research and development efforts to improve existing treatments, as well as increased collaboration among healthcare professionals to enhance CINV prevention and management strategies.
The global chemotherapy-induced nausea and vomiting market is primarily driven by the increasing prevalence of cancer worldwide, leading to a higher number of patients undergoing chemotherapy treatments. Additionally, the rising adoption of combination therapies and targeted drug delivery systems for more effective management of chemotherapy-induced symptoms is fueling market growth. Furthermore, the growing focus on developing innovative antiemetic drugs with improved efficacy and safety profiles, along with the expanding research and development activities in the oncology field, are contributing to the market expansion. Moreover, supportive government initiatives, awareness campaigns, and improving healthcare infrastructure in emerging economies are also driving the demand for chemotherapy-induced nausea and vomiting treatments.
Government policies related to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) market vary by country, but generally focus on ensuring access to effective antiemetic medications for cancer patients undergoing chemotherapy. Regulatory bodies such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe play a key role in approving and monitoring the safety and efficacy of CINV treatments. Reimbursement policies and national healthcare systems also influence patient access to these medications. Additionally, some governments may have initiatives to promote research and development in this area to improve the management of CINV and enhance patient outcomes. Overall, government policies aim to address the unmet needs of cancer patients experiencing CINV and facilitate the availability of effective treatments in the market.
The Global Chemotherapy-Induced Nausea and Vomiting (CINV) market is expected to witness steady growth in the coming years, driven by the increasing prevalence of cancer and the growing adoption of chemotherapy as a primary treatment option. The market is poised to benefit from advancements in antiemetic drugs and supportive care therapies, as well as the introduction of novel treatment options. Additionally, the rising focus on improving patient outcomes and quality of life during cancer treatment is likely to fuel the demand for effective CINV management solutions. However, challenges such as the high cost of therapies, side effects associated with antiemetic drugs, and the availability of alternative treatments may hinder market growth to some extent. Overall, the Global CINV market is projected to expand as healthcare providers and pharmaceutical companies continue to innovate and collaborate to address the unmet needs of cancer patients undergoing chemotherapy.
The Global Chemotherapy-Induced Nausea and Vomiting (CINV) market exhibits varying trends across regions. In Asia, the market is driven by the increasing prevalence of cancer and growing awareness about CINV management. North America leads the market due to advanced healthcare infrastructure and high adoption of innovative CINV treatment options. Europe follows closely with a rise in the geriatric population and government initiatives promoting cancer care. In the Middle East and Africa, the market growth is hindered by limited access to healthcare facilities and low awareness levels. Latin America shows potential for growth with improving healthcare facilities and rising investments in cancer treatment. Overall, the global CINV market is witnessing significant developments, with each region presenting unique opportunities and challenges for market players.
Global Chemotherapy-Induced Nauvomiting Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Chemotherapy-Induced Nauvomiting Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Chemotherapy-Induced Nauvomiting Market Revenues & Volume, 2021 & 2031F |
3.3 Global Chemotherapy-Induced Nauvomiting Market - Industry Life Cycle |
3.4 Global Chemotherapy-Induced Nauvomiting Market - Porter's Five Forces |
3.5 Global Chemotherapy-Induced Nauvomiting Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Chemotherapy-Induced Nauvomiting Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 Global Chemotherapy-Induced Nauvomiting Market Revenues & Volume Share, By Technology Type, 2021 & 2031F |
3.8 Global Chemotherapy-Induced Nauvomiting Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Global Chemotherapy-Induced Nauvomiting Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Global Chemotherapy-Induced Nauvomiting Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Chemotherapy-Induced Nauvomiting Market Trends |
6 Global Chemotherapy-Induced Nauvomiting Market, 2021 - 2031 |
6.1 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Product Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Serotonin (5-HT3) Receptor Antagonists, 2021 - 2031 |
6.1.3 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Neurokinin-1 (NK-1) Receptor Antagonists, 2021 - 2031 |
6.1.4 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Cannabinoids, 2021 - 2031 |
6.1.5 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Non-Pharmacological Therapies, 2021 - 2031 |
6.2 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Neurotransmitter Blockade, 2021 - 2031 |
6.2.3 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By CNS Pathway Modulation, 2021 - 2031 |
6.2.4 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Endocannabinoid System Modulation, 2021 - 2031 |
6.2.5 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Acupressure & Aromatherapy, 2021 - 2031 |
6.3 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By End User, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Oncology Patients, 2021 - 2031 |
6.3.3 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Cancer Treatment Centers, 2021 - 2031 |
6.3.4 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Cancer Survivors, 2021 - 2031 |
6.3.5 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Homecare & Alternative Medicine Centers, 2021 - 2031 |
6.4 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Application, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Delayed CINV Management, 2021 - 2031 |
6.4.3 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Prevention of Nausea and Vomiting, 2021 - 2031 |
6.4.4 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Symptom Relief, 2021 - 2031 |
6.4.5 Global Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Complementary CINV Management, 2021 - 2031 |
7 North America Chemotherapy-Induced Nauvomiting Market, Overview & Analysis |
7.1 North America Chemotherapy-Induced Nauvomiting Market Revenues & Volume, 2021 - 2031 |
7.2 North America Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Product Type, 2021 - 2031 |
7.4 North America Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
7.5 North America Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6 North America Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Application, 2021 - 2031 |
8 Latin America (LATAM) Chemotherapy-Induced Nauvomiting Market, Overview & Analysis |
8.1 Latin America (LATAM) Chemotherapy-Induced Nauvomiting Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Product Type, 2021 - 2031 |
8.4 Latin America (LATAM) Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
8.5 Latin America (LATAM) Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By End User, 2021 - 2031 |
8.6 Latin America (LATAM) Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Application, 2021 - 2031 |
9 Asia Chemotherapy-Induced Nauvomiting Market, Overview & Analysis |
9.1 Asia Chemotherapy-Induced Nauvomiting Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Product Type, 2021 - 2031 |
9.4 Asia Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
9.5 Asia Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By End User, 2021 - 2031 |
9.6 Asia Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Application, 2021 - 2031 |
10 Africa Chemotherapy-Induced Nauvomiting Market, Overview & Analysis |
10.1 Africa Chemotherapy-Induced Nauvomiting Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Product Type, 2021 - 2031 |
10.4 Africa Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
10.5 Africa Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By End User, 2021 - 2031 |
10.6 Africa Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Application, 2021 - 2031 |
11 Europe Chemotherapy-Induced Nauvomiting Market, Overview & Analysis |
11.1 Europe Chemotherapy-Induced Nauvomiting Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Product Type, 2021 - 2031 |
11.4 Europe Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
11.5 Europe Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By End User, 2021 - 2031 |
11.6 Europe Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Application, 2021 - 2031 |
12 Middle East Chemotherapy-Induced Nauvomiting Market, Overview & Analysis |
12.1 Middle East Chemotherapy-Induced Nauvomiting Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Product Type, 2021 - 2031 |
12.4 Middle East Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
12.5 Middle East Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By End User, 2021 - 2031 |
12.6 Middle East Chemotherapy-Induced Nauvomiting Market, Revenues & Volume, By Application, 2021 - 2031 |
13 Global Chemotherapy-Induced Nauvomiting Market Key Performance Indicators |
14 Global Chemotherapy-Induced Nauvomiting Market - Export/Import By Countries Assessment |
15 Global Chemotherapy-Induced Nauvomiting Market - Opportunity Assessment |
15.1 Global Chemotherapy-Induced Nauvomiting Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Chemotherapy-Induced Nauvomiting Market Opportunity Assessment, By Product Type, 2021 & 2031F |
15.3 Global Chemotherapy-Induced Nauvomiting Market Opportunity Assessment, By Technology Type, 2021 & 2031F |
15.4 Global Chemotherapy-Induced Nauvomiting Market Opportunity Assessment, By End User, 2021 & 2031F |
15.5 Global Chemotherapy-Induced Nauvomiting Market Opportunity Assessment, By Application, 2021 & 2031F |
16 Global Chemotherapy-Induced Nauvomiting Market - Competitive Landscape |
16.1 Global Chemotherapy-Induced Nauvomiting Market Revenue Share, By Companies, 2024 |
16.2 Global Chemotherapy-Induced Nauvomiting Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here